Retatrutide is not yet available through pharmaceutical channels
NICE issued a positive technology appraisal for semaglutide in 2023 , with NHS England targeting 35,000 patients in initial specialist weight management services
Large randomized trials including the LEADER, SUSTAIN, STEP, and SURMOUNT studies monitored thousands of patients and found that moderate heart rate increases during GLP-1 therapy did not increase the risk of heart attacks or strokes
Larger volumes take longer to inject, require more space in the subcutaneous tissue, and may produce a more noticeable lump immediately after injection
The clinical trial was 12 weeks, and it was powered as a proof-of-concept study
Without benzyl alcohol to inhibit bacterial growth, any contamination introduced during drawing can multiply rapidly